Articles tagged with Drug Therapy
A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...
Scientists developed an injectable therapy that protects the heart from damage after a heart attack by blocking the interaction between two proteins, Keap1 and Nrf2. The study showed decreased inflammation, cell death, and improved cardiac function in animal models.
Researchers developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure. The therapy both prompts the immune system to encourage tissue repair and promotes survival of heart muscle cells after a heart attack, showing effectiveness up to five weeks after injection.
A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.
Researchers developed a new model called React-OT that can predict the transition state of chemical reactions in under a second with high accuracy. The model uses linear interpolation to generate better initial guesses, reducing the number of steps and computation time needed.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
This review compares the bioactive components and medicinal properties of natural and cultivated O. sinensis, highlighting differences in composition and effectiveness for specific therapeutic uses. Polysaccharides, nucleosides, sterols, and amino acids contribute to their health benefits, with natural specimens often exhibiting higher...
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
A study by Johns Hopkins Medicine found that older adults with cancer benefit equally from immunotherapy treatments as younger patients, with key differences in their immune responses and cells. Researchers hope to develop new therapies tailored to different age groups' needs and improve treatment success.
A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.
Researchers at Penn's School of Dental Medicine and Perelman School of Medicine found that ACE inhibitors can inhibit the activity of ACE2, a critical cardioprotective enzyme. This discovery has implications for human patients prescribed these medications, who may benefit from additional ACE2 treatment.
Researchers from Radboud University Medical Center found that an existing drug can revive immune cells paralyzed by sepsis, a leading cause of death in ICUs. The study provides new perspectives for the treatment of sepsis and may lead to potential treatments for patients with immune paralysis.
Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.
Aging-associated mutations in the Dnmt3a gene boost mitochondria power in blood stem cells, leading to clonal hematopoiesis. New mitochondrial-targeting drugs show promise in treating age-related illnesses by selectively weakening mutated cells without impacting normal ones.
A UC Riverside-led study found that adult stem cells rely on histone chaperones to maintain their regenerative capacity. The researchers discovered that disrupting these proteins can lead to specific changes in stem cell identity, potentially guiding them into desired cell types.
Research found that certain diabetes medications associated with weight loss can contribute to muscle mass loss and increased risk of falls. The study identified three significant risk factors for falls: history of falls, use of SGLT2 inhibitors, and advanced age.
Researchers discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective treatment. Restoring this mechanism prevents progression of HFpEF and alleviates lipid overload in heart cells, providing molecular evidence for a promising therapeutic...
A new review from Marshall University researchers highlights emerging connections between gut health and sleep apnea, pointing to potential new therapeutic approaches for managing this common disorder. Alterations in gut microbiota composition have been consistently observed in individuals with sleep apnea, inducing systemic inflammati...
A research team has identified a key protein suspected to be involved in benzodiazepine-related inflammation, which could inform strategies to improve benzodiazepine drug design and treat inflammation-related conditions. The findings may lead to new treatments for diseases such as Alzheimer's, arthritis, and multiple sclerosis.
Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.
Researchers evaluated different types of Glasgow Outcome Scale Extended (GOSE) scores among US trauma center patients. They found that GOSE-All scores capture the combined effect of brain and extracranial injuries, while GOSE-TBI scores exclude extracranial injury effects.
Researchers at St. Jude Children's Research Hospital have designed a new drug framework that selectively targets the CYP3A4 enzyme, reducing off-target effects. The discovery provides a roadmap for future drug developers to better evaluate drug interactions and selectively target CYP proteins.
A new class of antibiotic has been shown to be effective in treating MRSA infections, with a daily dose of epidermicin NI01 demonstrating equal efficacy to the current standard of care. The findings justify further pre-clinical development and could lead to new gel-type therapies for skin infections.
A six-month study found that patients using GLP-1 and dual GLP-1/GIP receptor agonist therapy experienced minimal lean muscle mass loss as they lost weight. Regular resistance training, consistent protein intake, and close supervision by an expert obesity doctor were associated with better muscle retention.
STITCHR uses an RNA system to replace entire genes, overcoming CRISPR limitations in targeting every mutation. The tool offers a one-and-done approach for gene therapy, addressing cystic fibrosis and other diseases with thousands of mutations.
A new study found that mesenchymal stem cell-derived extracellular vesicles significantly enhance survival and facilitate substantial peripheral blood recovery in mice exposed to high-dose irradiation. The treatment promoted hematopoietic recovery, with increases in red blood cell, platelet, white blood cell, and hemoglobin levels.
Scientists have discovered a novel regulator of the mitochondrial sodium-calcium exchanger (NCLX), which helps maintain calcium balance in mitochondria. The discovery of TMEM65 could lead to new therapeutic agents to combat calcium overload associated with heart failure and Alzheimer's disease.
The 8th World Congress on Targeting Phage Therapy 2025 will bring together global phage community to address clinical, regulatory, and industrial challenges. The event will feature cutting-edge research, real-world clinical insights, and applications of bacteriophage therapy across medicine, oncology, agriculture, and industry.
Isowalsuranolide activates autophagy-dependent cell death by targeting TrxR1/2, leading to ROS-mediated lysosomal biogenesis and reduced cell growth. The study reveals the TrxR1/2-p53-TFEB/TFE3 axis as a key regulator of cellular homeostasis in cancer.
Researchers at Mayo Clinic developed a personalized deep brain stimulation platform to treat drug-resistant epilepsy. The study found that this approach reduced seizures while also improving memory and sleep in patients with temporal lobe epilepsy.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
Researchers at the University of Maryland discovered a way to predict treatment success for cutaneous leishmaniasis, a devastating skin infection. By analyzing a patient's immune system, they identified a distinctive pattern that distinguishes responders from non-responders, with 90% accuracy.
Researchers at Cornell University have discovered key neurological mechanisms in psilocybin's brain effects, targeting pyramidal tract neurons and serotonin receptors. This could enable pharmaceuticals to deliver mood-altering benefits while suppressing perceptual hallucinations.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A clinical study confirms that early treatment with fosdenopterin/rcPMP significantly reduces the risk of early death and promotes healthy brain development in infants with MoCD type A. The therapy restores the missing molybdenum cofactor, leading to improved developmental milestones.
Researchers found that NSD2 helps maintain MM cell identity by reorganizing DNA and influencing gene activity. This discovery could shape future treatment approaches for patients with t(4;14) myeloma.
The ALL ALS Consortium has recruited over 300 participants across two studies, ASSESS and PREVENT, aiming to disrupt traditional ALS research by making data and samples available worldwide. The consortium seeks to discover new drug targets and approaches for effective treatments.
The Finerenone Trial found that sudden death was the primary cause of higher cardiovascular mortality in patients with heart failure and mild or preserved ejection fractions. The study suggests that finerenone may not significantly impact cardiovascular mortality, but its effects on overall mortality are unclear.
A new study finds that prothrombin concentrate is superior to frozen plasma in controlling bleeding during heart surgery, reducing major bleeding events by nearly 50%. The concentrated product caused fewer adverse effects and saved hospitals resources, suggesting a potential shift in treatment guidelines.
The European Society of Cardiology has released a groundbreaking consensus statement on conduction system pacing, offering updated guidance for healthcare professionals on selecting patients. Conduction system pacing is being increasingly adopted due to its perceived ease of implantation and superior electrical performance.
A new class of zwitterionic phospholipids, DOPE-Cx, enhances the functional delivery of mRNA via lipid nanoparticles, overcoming endosomal escape and improving mRNA expression. This breakthrough paves the way for advanced therapeutic applications, including mRNA vaccines, cancer treatment, and protein replacement therapy.
Researchers found that digital PCR for BCR::ABL1 is more sensitive and accurate than conventional real-time quantitative PCR to detect ultralow levels of residual leukemic disease. The technology enabled the detection of stable deep molecular remission in 97% of patients, allowing for safe discontinuation of treatment.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
A team of scientists has created a new method to selectively modify specific proteins in complex biological environments. They achieved this using aptamers and deoxyoxanosine, allowing precise conjugation of desired sites on target proteins. This breakthrough technology has the potential to revolutionize cancer diagnosis and treatment.
Researchers at the University of Houston College of Pharmacy have identified a potential therapeutic target to repair injured muscles. They discovered that fibroblast growth factor–inducible 14 (Fn14) plays a crucial role in regulating satellite cell stability and function, which are responsible for muscle growth, repair, and regenerat...
Researchers analyzed trends in efficacy endpoints for glioblastoma phase II clinical trials, finding a shift towards using time-to-event measures like progression-free survival (PFS) and overall survival (OS). This trend reflects the complexity of GBM treatment evaluation and may indicate evolving clinical trial design.
A new study found that recombinant adeno-associated virus (rAAV) capsids contain single-stranded DNA impurities derived from plasmid and host cell DNA. The researchers suggest that the adverse effects of these impurities may differ from those of double-stranded DNA, highlighting the need for further evaluation.
The INHALE-3 extension study found that a regimen of inhaled technosphere insulin and insulin degludec reduced post-meal hyperglycemia in adults with type 1 diabetes. The treatment showed significant improvements in mean time in range, with 43% of participants expressing interest in continuing the regimen.
Crew-9 astronauts conducted research on protein crystallization studies and a new drug for Alzheimer's, dementia, and Parkinson's. They also supported student-led experiments, contributing to the next generation of explorers.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
A Rice University statistician has received a $1 million CPRIT award to advance AI-powered precision medicine for prostate cancer. The project aims to identify lethal forms of prostate cancer earlier and improve treatment selection using AI tools and advanced imaging techniques.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
Virginia Tech researchers Pamela VandeVord and Gunnar Brolinson received a $2.17 million grant to investigate cranial osteopathic manual manipulation as a potential treatment for traumatic brain injury symptoms, particularly headaches. The noninvasive technique aims to enhance brain fluid motion and balance the autonomic nervous system.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers discover edonerpic maleate enhances neural plasticity, supporting cortical reorganization and improving motor control in non-human primates with SCI. The compound promotes AMPA receptor movement to areas responsible for motor control, strengthening existing neural connections.
Researchers have discovered how severe COVID-19 can destroy immune cells' ability to repair the lungs, leading to lingering effects of long COVID. By enhancing damaged organelles using a FDA-approved drug, they found improved lung healing and reduced inflammation.
Researchers have discovered a new diterpene-based drug that facilitates the repopulation of mature functional neurons in brain regions damaged by traumatic injuries. The study found that these new cells are integrated into neural circuits and develop functional characteristics similar to those eliminated by the injury.